Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation

Cancer Letters

Volumn 385, Issue , 2017, Pages 207-214

  Wu, Fei ^a,b   Dai, Xiangpeng ^b   Gan, Wenjian ^b   Wan, Lixin ^b,c   Li, Min ^d   Mitsiades, Nicholas ^d   Wei, Wenyi ^b   Ding, Qiang ^a   Zhang, Jinfang ^b  

^a FUDAN UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Cdc20; Degradation; SPOP; Ubiquitination

Indexed keywords

ADAPTOR PROTEIN; CELL CYCLE PROTEIN 20; CULLIN; CULLIN 1; CULLIN 3; PEVONEDISTAT; SPECKLE TYPE POZ PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ANTINEOPLASTIC AGENT; APCIN; CARBAMIC ACID DERIVATIVE; CDC20 PROTEIN, HUMAN; CUL3 PROTEIN, HUMAN; CYCLOPENTANE DERIVATIVE; DIAMINE; ENZYME INHIBITOR; NUCLEAR PROTEIN; PYRIMIDINE DERIVATIVE; REPRESSOR PROTEIN; SPOP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MUTANT; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN INTERACTION; UBIQUITINATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HELA CELL LINE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROSTATIC NEOPLASMS; PROTEIN DOMAIN; TIME FACTOR;

ANTINEOPLASTIC AGENTS; CARBAMATES; CDC20 PROTEINS; CULLIN PROTEINS; CYCLOPENTANES; DIAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HELA CELLS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; PYRIMIDINES; REPRESSOR PROTEINS; TIME FACTORS; TRANSFECTION; UBIQUITINATION;

EID: 85002496970     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.10.021     Document Type: Article

References (48)

1. [1] Frescas, D., Pagano, M., Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 8 (2008), 438–449.
2. [2] Wang, Z., Liu, P., Inuzuka, H., Wei, W., Roles of F-box proteins in cancer. Nat. Rev. Cancer 14 (2014), 233–247.
3. [3] Nakayama, K.I., Nakayama, K., Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6 (2006), 369–381.
4. [4] Zhang, J., Wan, L., Dai, X., Sun, Y., Wei, W., Functional characterization of anaphase promoting complex/cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim. Biophys. Acta 1845 (2014), 277–293.
5. [5] Peters, J.M., The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat. Rev. Mol. Cell Biol. 7 (2006), 644–656.
6. [6] King, R.W., Deshaies, R.J., Peters, J.M., Kirschner, M.W., How proteolysis drives the cell cycle. Science 274 (1996), 1652–1659.
7. [7] Yu, H., Cdc20: a WD40 activator for a cell cycle degradation machine. Mol. Cell 27 (2007), 3–16.
8. [8] Huang, J.N., Park, I., Ellingson, E., Littlepage, L.E., Pellman, D., Activity of the APC(Cdh1) form of the anaphase-promoting complex persists until S phase and prevents the premature expression of Cdc20p. J. Cell Biol. 154 (2001), 85–94.
9. [9] Kidokoro, T., Tanikawa, C., Furukawa, Y., Katagiri, T., Nakamura, Y., Matsuda, K., CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27 (2008), 1562–1571.
10. [10] Manchado, E., Guillamot, M., de Carcer, G., Eguren, M., Trickey, M., Garcia-Higuera, I., et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha, delta phosphatase. Cancer Cell 18 (2010), 641–654.
11. [11] Huang, H.C., Shi, J., Orth, J.D., Mitchison, T.J., Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16 (2009), 347–358.
12. [12] Zeng, X., Sigoillot, F., Gaur, S., Choi, S., Pfaff, K.L., Oh, D.C., et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 18 (2010), 382–395.
13. [13] Wan, L., Tan, M., Yang, J., Inuzuka, H., Dai, X., Wu, T., et al. APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev. Cell 29 (2014), 377–391.
14. [14] Sackton, K.L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T.B., et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature, 2014.
15. [15] Mao, Y., Li, K., Lu, L., Si-Tu, J., Lu, M., Gao, X., Overexpression of Cdc20 in clinically localized prostate cancer: relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark. 16 (2016), 351–358.
16. [16] Jiang, J., Jedinak, A., Sliva, D., Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA. Biochem. Biophys. Res. Commun. 415 (2011), 325–329.
17. [17] Rajkumar, T., Sabitha, K., Vijayalakshmi, N., Shirley, S., Bose, M.V., Gopal, G., et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer, 11, 2011, 80.
18. [18] Marucci, G., Morandi, L., Magrini, E., Farnedi, A., Franceschi, E., Miglio, R., et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch. 453 (2008), 599–609.
19. [19] Ouellet, V., Guyot, M.C., Le Page, C., Filali-Mouhim, A., Lussier, C., Tonin, P.N., et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int. J. Cancer 119 (2006), 599–607.
20. [20] Petroski, M.D., Deshaies, R.J., Function and regulation of cullin-RING ubiquitin ligases. Nature Rev. Mol. Cell Biol. 6 (2005), 9–20.
21. [21] Lee, A.E., Castaneda, C.A., Wang, Y., Fushman, D., Fenselau, C., Preparing to read the ubiquitin code: a middle-out strategy for characterization of all lysine-linked diubiquitins. J. Mass Spectrom. 49 (2014), 1272–1278.
22. [22] Zhou, W., Wei, W., Sun, Y., Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases. Cell Res. 23 (2013), 599–619.
23. [23] Genschik, P., Sumara, I., Lechner, E., The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J. 32 (2013), 2307–2320.
24. [24] Berger, M.F., Lawrence, M.S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A.Y., et al. The genomic complexity of primary human prostate cancer. Nature 470 (2011), 214–220.
25. [25] Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.P., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44 (2012), 685–689.
26. [26] s.c.m.o. Cancer Genome Atlas Research Network. Electronic address, N. Cancer Genome Atlas Research, The molecular taxonomy of primary prostate Cancer. Cell 163 (2015), 1011–1025.
27. [27] Zhuang, M., Calabrese, M.F., Liu, J., Waddell, M.B., Nourse, A., Hammel, M., et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 36 (2009), 39–50.
28. [28] Hernandez-Munoz, I., Lund, A.H., van der Stoop, P., Boutsma, E., Muijrers, I., Verhoeven, E., et al. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 7635–7640.
29. [29] Zhang, Q., Shi, Q., Chen, Y., Yue, T., Li, S., Wang, B., et al. Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 21191–21196.
30. [30] An, J., Wang, C., Deng, Y., Yu, L., Huang, H., Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 6 (2014), 657–669.
31. [31] Geng, C., Rajapakshe, K., Shah, S.S., Shou, J., Eedunuri, V.K., Foley, C., et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 74 (2014), 5631–5643.
32. [32] Geng, C., He, B., Xu, L., Barbieri, C.E., Eedunuri, V.K., Chew, S.A., et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6997–7002.
33. [33] Theurillat, J.P., Udeshi, N.D., Errington, W.J., Svinkina, T., Baca, S.C., Pop, M., et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346 (2014), 85–89.
34. [34] An, J., Ren, S., Murphy, S.J., Dalangood, S., Chang, C., Pang, X., et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59 (2015), 904–916.
35. [35] Gan, W., Dai, X., Lunardi, A., Li, Z., Inuzuka, H., Liu, P., et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate Cancer progression. Mol. Cell 59 (2015), 917–930.
36. [36] Zhu, H., Ren, S., Bitler, B.G., Aird, K.M., Tu, Z., Skordalakes, E., et al. SPOP E3 ubiquitin ligase adaptor promotes cellular senescence by degrading the SENP7 deSUMOylase. Cell Rep. 13 (2015), 1183–1193.
37. [37] Li, G., Ci, W., Karmakar, S., Chen, K., Dhar, R., Fan, Z., et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 25 (2014), 455–468.
38. [38] Evangelou, K., Havaki, S., Kotsinas, A., E2F transcription factors and digestive system malignancies: how much do we know?. World J. Gastroenterol. 20 (2014), 10212–10216.
39. [39] Nawrocki, S.T., Griffin, P., Kelly, K.R., Carew, J.S., MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin. Investig. Drugs 21 (2012), 1563–1573.
40. [40] Soucy, T.A., Smith, P.G., Milhollen, M.A., Berger, A.J., Gavin, J.M., Adhikari, S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458 (2009), 732–736.
41. [41] Duda, D.M., Borg, L.A., Scott, D.C., Hunt, H.W., Hammel, M., Schulman, B.A., Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 134 (2008), 995–1006.
42. [42] Hyun, S.Y., Sarantuya, B., Lee, H.J., Jang, Y.J., APC/C(Cdh1)-dependent degradation of Cdc20 requires a phosphorylation on CRY-box by Polo-like kinase-1 during somatic cell cycle. Biochem. Biophys. Res. Commun. 436 (2013), 12–18.
43. [43] Zhang, Q., Zhang, L., Wang, B., Ou, C.Y., Chien, C.T., Jiang, J., A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev. Cell 10 (2006), 719–729.
44. [44] Kwon, J.E., La, M., Oh, K.H., Oh, Y.M., Kim, G.R., Seol, J.H., et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J. Biol. Chem. 281 (2006), 12664–12672.
45. [45] Verma, R., Peters, N.R., D'Onofrio, M., Tochtrop, G.P., Sakamoto, K.M., Varadan, R., et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306 (2004), 117–120.
46. [46] Li, C., Ao, J., Fu, J., Lee, D.F., Xu, J., Lonard, D., et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 30 (2011), 4350–4364.
47. [47] Wang, Z., Wan, L., Zhong, J., Inuzuka, H., Liu, P., Sarkar, F.H., et al. Cdc20: a potential novel therapeutic target for cancer treatment. Curr. Pharm. Des. 19 (2013), 3210–3214.
48. [48] Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z., Wei, W., Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol. Ther. 151 (2015), 141–151.